Tagged with R

China Olivier Dessajan, CEO of Colisée China and Co-President of the French Healthcare Alliance, discusses Colisée’s long-term investment strategies in China, the challenges of navigating the local regulatory environment, and the importance of French-Chinese healthcare collaborations.   French companies are committed to the Chinese market, offering superior products and solutions to…

Saudi Arabia Saudi Arabia – by many measures the cultural, social, and economic epicentre of the Arab and Islamic worlds – is currently undergoing a once-in-a-lifetime transfiguration. The country’s ‘Vision 2030’ transformation plan has not only been radically reshaping the national economy and reducing its dependence on petroleum revenues but has also…

Switzerland Lucas Schalch of Intergenerika examines the challenges confronting Switzerland’s generic and biosimilar sectors, such as high production costs and changing regulations. Schalch underscores the importance of maintaining a favourable economic environment for these industries.   We must work together to sustain a healthy and competitive market, ensuring that the generic…

Mexico David López García, a pharma industry executive and rare disease expert, discusses the challenges and advancements in treating rare diseases in Mexico. He highlights the importance of public-private partnerships and the growing interest from industry in the rare disease field.   Every day is an opportunity to make a difference…

China Dr George Chen explores D3 Bio’s strategic approach to drug development, its ambition to launch two cancer therapies in the US within five years, and the critical role of partnerships and funding in achieving these goals. Reflecting on this journey, Dr. Chen emphasizes, “It’s a journey to realize a dream…

Mexico Stendhal Pharma operates with an “unlimited pipeline” approach by forming strategic alliances with global pharmaceutical companies that lack a presence in Latin America. Rodrigo Ruiz Mingramm explains how, as companies reconsider their direct presence in Latin America due to political and socio-economic uncertainties, Stendhal’s model is becoming more appealing, and…

Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…

Mexico The Swiss Chamber in Mexico (SwissCham) represents Swiss companies operating in Mexico, a country that has become Switzerland’s top commercial partner in Latin America. Executive Director Emilia Pfeiffer outlines the role of SwissCham, the robust presence of the Swiss healthcare and life sciences companies in the country, the Chamber’s advocacy…

Mexico The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents more than 60 of the country’s research-based pharmaceutical companies. Executive director Larry Rubin, who took on the association’s leadership six months ago, outlines his priorities, such as building public awareness and stronger relationships with the government. He also weighs in on…

Mexico Gilead’s Mexican affiliate is its largest in the LatAm region, and one that has had an impressive impact as 85 percent of those living with HIV in the country are treated with the company’s therapies. With just seven months behind him as GM, Arturo de la Rosa explains what is…

China Adept at identifying promising biotechs, Qiming Venture Partners-backed companies saw no less than eight IPOs last year. Managing Partner Nisa Leung provides an update on the firm’s activities in light of current China-US geopolitical tensions and the evolving business development models that have become more focused on licensing innovative drugs…

Hong Kong Professor at the Chinese University of Hong Kong since 1993 and pioneer in studying the causes of stroke in China, Lawrence Wong comments on neurology advancements over the past 30 years; the increasing number of Alzheimer’s cases amongst Asian populations, and the need to go from a symptomatic approach to…